MyBlueDotsAlentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis MyBlueDots4 weeks ago01 mins BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile Post navigation Previous: Henry Schein Opens Customer Emergency Support Hotline in Response to California FiresNext: What Illinois residents should know, following the first US death from bird virus
GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds MyBlueDots7 hours ago 0
Review finds women health sector leaders good for a nation’s wealth, health, innovation, ethics MyBlueDots7 hours ago 0